PS-341 in Treating Patients With Hematologic Cancer
Status:
Completed
Trial end date:
2001-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth.
PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have
hematologic cancer.